Blocking Palmitoylation of Apelin Receptor Alleviates Morphine Tolerance in Neuropathic Cancer Pain
Open Access
- 1 January 2024
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (1) , 47-60
Abstract
Neuropathic cancer pain (NCP) is an important symptom in patients with cancer. However, significant analgesic tolerance and other side effects critically hamper the administration of morphine. Protein palmitoylation mediated by the DHHC family may be involved in the glial activation and inflammatory responses underlying organ failure. In this study, we investigated the key role of protein palmitoylation in cancer pain and sought to target palmitoylation to suppress morphine tolerance. We found that long-term use of morphine led to the accumulation of the morphine metabolite, morphine-3-glucuronide, in vivo and activated ERK1/2 and microglia to release inflammatory factors through the apelin receptor APLNR. Palmitoyltransferase ZDHHC9 was upregulated in NCP, and APLNR was palmitylated to protect it from lysosomal degradation and to maintain its stability. We also designed competitive inhibitors of APLNR palmitoylation to inhibit the development of NCP, release of inflammatory factors, and attenuation of morphine tolerance. Therefore, targeting APLNR palmitoylation in combination with morphine is a potent method for cancer pain treatment. Our data provide a basis for the future clinical use of related drugs combined with morphine for the treatment of cancer-related pain.Keywords
This publication has 44 references indexed in Scilit:
- Efficacy and ligand bias at the μ‐opioid receptorBritish Journal of Pharmacology, 2013
- Putting proteins in their place: Palmitoylation in Huntington disease and other neuropsychiatric diseasesProgress in Neurobiology, 2012
- Protein palmitoylation in neuronal development and synaptic plasticityNature Reviews Neuroscience, 2010
- Opioids Switching with Transdermal Systems in Chronic Cancer PainJournal of Experimental & Clinical Cancer Research, 2009
- Toll-like receptors in neurodegenerationBrain Research Reviews, 2009
- 2-Bromopalmitate and 2-(2-hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one inhibit DHHC-mediated palmitoylation in vitroJournal of Lipid Research, 2009
- Discovery of protein-palmitoylating enzymesPflügers Archiv - European Journal of Physiology, 2008
- Protein lipidationThe FEBS Journal, 2007
- Pain control in cancer: recent findings and trendsAnnals of Oncology, 2007
- Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer painPain, 2005